Houssam Al Kharrat

Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study

Marc Ferrante, Geert D’Haens, Vipul Jairath et al. · The Lancet · 2024 · 76 citations

Moderately-to-severely Active Crohn, Immunology, Gastroenterology +5

Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies

David T. Rubin, Jessica R. Allegretti, Julián Panés et al. · The Lancet · 2024 · 62 citations · Full text

Placebo-controlled Induction, Gastroenterology, Pathology +6

Serum drug concentrations of INH and RMP predict 2-month sputum culture results in tuberculosis patients

Allison Mah, Houssam Al Kharrat, Rabia Ahmed et al. · The International Journal of Tuberculosis and Lung Disease · 2015 · 25 citations

Usefulness of exercise echocardiography in predicting cardiac events in an outpatient population

Mushabbar Syed, Qahtan Al-Malki, Ghassan Kazmouz et al. · The American Journal of Cardiology · 1998 · 15 citations

Physical Activity, Cardiovascular Disease, Exercise Echocardiography +11

Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial

Brian G. Feagan, Bruce E Sands, Corey A. Siegel et al. · ˜The œLancet. Gastroenterology & hepatology · 2025 · 13 citations